Follistatin 344: gene therapy, fragments and muscle claims
Follistatin is a protein involved in signaling by members of the TGF-beta family. “Follistatin 344” appears in experimental gene-transfer literature, but that does not mean an injectable product sold with the same number reproduces the intervention. The distinction between a gene construct, its processed protein and a short inhibitory fragment is central to evaluating muscle-growth claims.
Identity and formulation
A gene-transfer study delivers instructions for cells to produce a protein; administering a manufactured protein is a different intervention. Expression, tissue distribution and duration cannot be assumed to match.
The 14-amino-acid experimental fragment DF-3 is not full-length follistatin 344. An experiment on the fragment cannot establish the efficacy or selectivity of another preparation.
What the studies show
The checked fragment study reported myostatin inhibition in a cell assay and increased muscle mass in mice. Separately, a small FS344 gene-transfer trial studied six people with Becker muscular dystrophy. Neither intervention is equivalent to injecting a retail protein preparation.
| Study and design | Finding | What it does not establish |
|---|---|---|
| A follistatin-derived inhibitory fragment
In-vitro signaling assay and mouse experiment Reading scope: PubMed abstract |
DF-3 inhibited myostatin in the assay and increased skeletal muscle mass in mice; the assay did not show inhibition of activin A or TGF-beta1. | This is evidence about a specific short fragment, not a retail FS344 protein or a human muscle-building regimen. |
| FS344 gene transfer in Becker muscular dystrophy
Small phase 1/2a gene-transfer trial in six patients Reading scope: PubMed abstract |
Some participants improved walking distance while others did not; the paper reported tissue changes after vector delivery. | The very small study and different delivery intervention cannot validate a protein vial or performance-enhancement claim. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
Muscle mass, muscle strength and useful physical function are not identical outcomes. Even a genuine increase in experimental muscle size needs separate evaluation for performance, durability and harms.
A claim of selective myostatin inhibition should name the exact molecule and show its assay results. It should not be copied from one fragment to all follistatin products. Similarly, gene-transfer research in a muscle disease cannot automatically support performance enhancement in otherwise healthy people.
A gene-therapy report should identify its vector and expressed protein; a protein study should identify the manufactured molecule and activity. Without those distinctions, even a technically correct citation can be attached to the wrong intervention.
Safety context
Intervening in growth-regulating pathways can have consequences outside the desired muscle outcome. The selected mouse and assay data do not establish the long-term systemic safety of an unverified protein preparation.
Study exposure and units
Neither a gene-vector amount nor an injected fragment amount can be turned into a protein-vial regimen by a unit conversion. They describe different interventions.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Request the exact isoform, mature sequence, expression system and relevant activity assay. A total protein concentration alone does not show that the protein has the expected structure or functional activity.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Does FS344 gene therapy validate a follistatin vial?
No. Gene delivery and injected protein differ in what is administered and how exposure is produced. Matching a label is not enough to establish equivalence.
Is DF-3 another name for follistatin 344?
No. The checked paper describes a much shorter derived fragment. Its selectivity and mouse findings must remain attached to that fragment.
Sources
- A follistatin-derived inhibitory fragment (PubMed abstract)
- FS344 gene-transfer trial (PubMed abstract)